(Q38796315)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27038323%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

title

PDE4B as a microglia target to reduce neuroinflammation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27038323%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27038323%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

Damien D Pearse

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27038323%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

publication date

1 April 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27038323%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27038323%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27038323%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27038323%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

page(s)

1698-1709

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27038323%20AND%20SRC:MED&resulttype=core&format=json

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study

31 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Expression of the specific type IV phosphodiesterase gene PDE4B3 during different phases of long-term potentiation in single hippocampal slices of rats in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Local self-renewal can sustain CNS microglia maintenance and function throughout adult life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Mitogen-activated protein kinases in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Modulation of the cAMP signaling pathway after traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Selective Phosphodiesterase 4B Inhibitors: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Central nervous system myeloid cells as drug targets: current status and translational challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Identification of a unique TGF-β-dependent molecular and functional signature in microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

ATP mediates rapid microglial response to local brain injury in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Structural basis for the design of selective phosphodiesterase 4B inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Synthesis of [(11)C]GSK1482160 as a new PET agent for targeting P2X(7) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Microglial diversity by responses and responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

The interplay between cyclic AMP, MAPK, and NF-κB pathways in response to proinflammatory signals in microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Fate mapping analysis reveals that adult microglia derive from primitive macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Regulation of microglial proliferation during chronic neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives as highly selective PDE4B inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Target site occupancy: emerging generalizations from clinical and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Discovery of triazines as selective PDE4B versus PDE4D inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Microglia: active sensor and versatile effector cells in the normal and pathologic brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Endotoxin-induced systemic inflammation activates microglia: [¹¹C]PBR28 positron emission tomography in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Neuroinflammation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Depression pathogenesis and treatment: what can we learn from blood mRNA expression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

The microglial sensome revealed by direct RNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Keynote review: phosphodiesterase-4 as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Phosphodiesterases in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Microglia in the TBI brain: The good, the bad, and the dysregulated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Evidence for brain glial activation in chronic pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Blockade of PDE4B limits lung vascular permeability and lung inflammation in LPS-induced acute lung injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Cerebrospinal fluid antimicroglial antibodies in Alzheimer disease: a putative marker of an ongoing inflammatory process

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Microglial malfunction: the third rail in the development of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Discovery of selective PDE4B inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Transglutaminase 2 accelerates neuroinflammation in amyotrophic lateral sclerosis through interaction with misfolded superoxide dismutase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Tumor necrosis factor reduces cAMP production in rat microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Interferon-gamma and lipopolysaccharide reduce cAMP responses in cultured glial cells: reversal by a type IV phosphodiesterase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Microglial physiology: unique stimuli, specialized responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

The benefits and detriments of macrophages/microglia in models of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

PDE4 as a target for cognition enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Ferritin stimulates oligodendrocyte genesis in the adult spinal cord and can be transferred from macrophages to NG2 cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Cyclic AMP: master regulator of innate immune cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

PDE4 inhibitors: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

NF-kappaB: a key role in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Inhibition of the NF-kappaB transcriptional activity by protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Identification of a chronic non-neurodegenerative microglia activation state in a mouse model of peroxisomal β-oxidation deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Priming the inflammatory pump of the CNS after traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

A review of the relationship between proinflammatory cytokines and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

Intrathecal injection of phosphodiesterase 4B-specific siRNA attenuates neuropathic pain in rats with L5 spinal nerve ligation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

7 January 2021

In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

7 January 2021

Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

7 January 2021

Lipopolysaccharide-induced microglial activation in culture: temporal profiles of morphological change and release of cytokines and nitric oxide

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

7 January 2021

Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

7 January 2021

Transcriptional response of human microglial cells to interferon-gamma

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

7 January 2021

Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

7 January 2021

Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

7 January 2021

Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22986

7 January 2021

Identifiers

DOI

10.1002/GLIA.22986

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27038323%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference